In the course of the development of the TF-targeting concept and therapeutic agents using fVII, Hu and Garen (2000, 2001) constructed the first TF-targeting agent, an fVII/IgG1 Fc immunoconjugate (called an Icon) for immunotherapy of cancer (Hu et al, 1999). The gene discussed is TF; the disease is cancer.